A BRIEF REVIEW ON SCREENING MODELS FOR HYPERLIPIDEMIA

Hyperlipidemia is a significant contributor to the global burden of cardiovascular diseases, such as coronary heart disease and stroke. Characterized by elevated plasma lipids, including cholesterol, triglycerides, and lipoproteins, hyperlipidemia is a prevalent health issue with increasing incidence in both developed and developing countries. According to the World Health Organization (WHO), raised cholesterol levels are linked to 4.5% of global deaths and account for 29.7 million disability-adjusted life years (DALYs) annually. The Fredrickson classification system, endorsed by WHO, categorizes hyperlipidemia into six types based on lipoprotein abnormalities, providing a foundation for understanding its diverse etiologies and clinical implications. Experimental induction of hyperlipidemia is pivotal for studying its pathophysiology and testing potential therapeutic interventions. Various screening methods have been developed, including the use of pharmacological agents, dietary modifications, and genetic models. This review discusses the epidemiology, classification, and methodologies used to induce hyperlipidemia in experimental settings, highlighting their relevance in advancing our understanding and management of this critical public health challenge.